Natera, Inc.

NTRA Healthcare Diagnostics & Research

Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.

Revenue
+34.1%
EPS
+34.4%
Free cash flow
−85.8%
Total debt
−0.06%

Quarter to September 2026, against a year earlier

308.09 55.67 −15.30%
Market cap
$52.4B
P/E
0.0×
Fwd P/E
−289×
Dividend yield
—
F-score
6/9
Altman Z
26.84
Beneish M
−2.17
Dividend safety
n/a

Natera, Inc. 10-K filed Feb 27, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 9:31 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business, against the 10-K filed Feb 28, 2025: 18 added · 12 removed · 75 modified; 10 with only figures updated; 1 moved without change

  1. Modified · Overview

    We are a diagnostics company with proprietary molecular and bioinformatics technology that we are applying to change thedisease management of disease worldwide. Our cell-free DNA, or cfDNA, technology combines our novel molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell, with our statistical algorithms whichthat incorporate data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with high accuracy and coverage. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier and provide more targeted interventions that help lead to longer, healthier lives.

104 more changes in this Item, word by word, in Powerpack.